Identification of factors and outcomes of trust in mobile supply chains by Nassim Ghondaghsaz, Sven Engesser

“…Second, the authors conducted semi-structured interviews in chemical and pharmaceutical companies in Germany. These organizations stand out as leaders in the concept of MSCs and have developed collaborations with various stakeholders. …”
Get full text

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic by Pavel Jansa, David Ambrož, Matyáš Kuhn, Vladimír Dytrych, Michael Aschermann, Vladimír Černý, Virginie Gressin, Samuel Heller, Jan Kunstýř, Michal Širanec, Ci Song, Aleš Linhart, Jaroslav Lindner, Audrey Muller

Get full text

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studi... by Dennis McGonagle, Iain B. McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Stephen Xu, Christopher T. Ritchlin, Proton Rahman, Phillip J. Mease

Get full text

Knowledge of drug prescription in dentistry students by Guzmán-Álvarez R, Medeiros M, Reyes-Lagunes LI, Campos-Sepúlveda AE

“…The sources of information used by students for prescribing drugs included the professors at the clinics (n = 49, 74.2%), the pharmacology course (n = 7, 10.7%), medical dictionary consultation (n = 15, 22.72%), classmate support (n = 3, 4.54%), and information provided by medical representatives from pharmaceutical companies (n = 1, 1.5%). Finally, only 20 students (30.3%) followed the WHO Guide to Good Prescribing, 40 students acknowledged not following it (60.6%), and six students (9.1%) had no knowledge of it.Conclusion: The knowledge of pharmacology among fourth-year students in the School of Dentistry has gaps that could affect patient safety. …”
Get full text

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors by James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong

Get full text

Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized... by Clément Palpacuer, Bruno Laviolle, Rémy Boussageon, Jean Michel Reymann, Eric Bellissant, Florian Naudet

“…<h4>Methods and findings</h4>Three reviewers searched for published and unpublished studies in Medline, the Cochrane Library, Embase, ClinicalTrials.gov, Current Controlled Trials, and bibliographies and by mailing pharmaceutical companies, the European Medicines Agency (EMA), and the US Food and Drug Administration. …”
Get full text

ROLE OF COMMUNITY PHARMACIST IN PHARMACOVIGILENCE by Nayab Farooq, Fatima Amin

“…This program collects information from medicals professionals, pharmaceutical companies and patients on ADRs.6 Role of Pharmacist The professional responsibility of community pharmacist is far more than just preparing and dispensing medicines. …”
Get full text

Lack of high BMI-related features in adipocytes and inflammatory cells in the infrapatellar fat pad (IFP) by Anja J. de Jong, Inge R. Klein-Wieringa, Stefan N. Andersen, Joanneke C. Kwekkeboom, Linda Herb-van Toorn, Badelog J. E. de Lange-Brokaar, Danny van Delft, John Garcia, Wu Wei, Huub J. L. van der Heide, Yvonne M. Bastiaansen-Jenniskens, Gerjo J. V. M. van Osch, Annemarie M. Zuurmond, Vedrana Stojanovic-Susulic, Rob G. H. H. Nelissen, René E. M. Toes, Margreet Kloppenburg, Andreea Ioan-Facsinay

Get full text

Process systems engineering of continuous pharmaceutical manufacturing by Abel, Matthew J

Get full text

Biosynthetic engineering for the assembly of better drugs by Yadav, Vikramaditya Ganapati

Get full text

Biofabrication of choroid-retina tissue construct for modelling of age-related macular degeneration disease by Tan, Edgar Yong Sheng

“…The resultant tissue construct could be used a possible tissue model to be employed in pharmaceutical companies for drug testing of AMD patients.…”
Get full text
Get full text

Professional doctorate in health psychology thesis portfolio (Wehling : 2019) by Wehling, Helena

“…Before I was offered my first job in April 2015, I engaged in voluntary work with patients as well as doing an internship for an interventional trial at King’s College London, until I was offered a full-time job role in a commercial agency who were specialised in developing patient support programmes across a wide range of chronic conditions for many of the leading international pharmaceutical companies. As there was a strong focus on international collaborations both internally and with many clients being located in central Europe, my role then expanded to additionally becoming the representative Health Psychology Specialist for the German office in Frankfurt. …”
Get full text

What doesn't work and how to show it

“…McPherson and Hemminki argue that if trials done by pharmaceutical companies to obtain drug licences had to include adequate data on harms and ineffectiveness we could learn much more quickly what we need to know about new drugs (p 518).9 Pound et al propose systematic reviews and meta-analyses of the animal studies that supposedly underpin much human clinical research.10 Such reviews could assess the validity and generalisability to humans of animal research and could prevent unnecessary treatment trials. …”

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis by Leucht, S, Örey, D, Richter, F, Samara, M, Kissling, W, Stapf, M, Lässig, B, Cipriani, A, Barbui, C, Spineli, L, Mavridis, D, Salanti, G, Engel, R, Geddes, J, Davis, J

“…Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. …”

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. by Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, R, Geddes, J, Kissling, W, Stapf, M, Lässig, B, Salanti, G, Davis, J

“…Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. …”

Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis by Karlsson, WK, Ostinelli, EG, Zhuang, ZA, Kokoti, L, Christensen, RH, Al-Khazali, HM, Deligianni, CI, Tomlinson, A, Ashina, H, Ruiz de la Torre, E, Diener, H, Cipriani, A, Ashina, M

“…Data sources: Cochrane Central Register of Controlled Trials, Medline, Embase, ClinicalTrials.gov, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform, as well as websites of regulatory agencies and pharmaceutical companies without language restrictions until 24 June 2023. …”

Oxcarbazepine for acute affective episodes in bipolar disorder. by Vasudev, A, Macritchie, K, Vasudev, K, Watson, S, Geddes, J, Young, A

“…Authors, experts in the field and pharmaceutical companies were contacted requesting information on published and unpublished trials. …”

A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis by Francisco Gómez-García, Francisco Gómez-García, Pedro Jesús Gómez-Arias, Pedro Jesús Gómez-Arias, Ana Montilla-López, Jorge Hernández-Parada, Juan Luís Sanz-Cabanillas, Juan Luís Sanz-Cabanillas, Juan Ruano, Juan Ruano, Esmeralda Parra-Peralbo

“…Knowledge articles are mainly created and published by pharmaceutical companies and authors through their own funding or by those related to them. …”
Get full text

Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi by Mahmoud M. Bendary, Marwa I. Abd El-Hamid, Amira I. Abousaty, Arwa R. Elmanakhly, Walaa A. Alshareef, Rasha A. Mosbah, Majid Alhomrani, Mohammed M. Ghoneim, Amr Elkelish, Nada Hashim, Abdulhakeem S. Alamri, Helal F. Al-Harthi, Nesreen A. Safwat

“…From our findings, we anticipate that pharmaceutical companies will be able to utilize new combinations against resistant pathogens.…”
Get full text

An Interview with Tom Beauchamp, Early Bioethics Innovator by Elizabeth Galt

“…A:        There’s no doubt in my mind that many of the technologies under development will come from pharmaceutical companies. Pharmaceutical companies are private corporations, and they are global institutions. …”
Get full text